Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebound ...More

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the previous quarter. The results included a Rs 20 crore gratuity credit and a Rs 25 crore exceptional loss from employee termination benefits, alongside management changes. ...Less

The country’s largest biopharmaceutical company’s net profits before exceptional items grew by 11% to Rs ...More

The country’s largest biopharmaceutical company’s net profits before exceptional items grew by 11% to Rs 188 crore in the quarter, it reported on Thursday night. ...Less

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus ...More

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. The gross R&D spends grew 10% YoY to Rs 278 crore in Q2FY24. ...Less

Total revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY22 ...More

Total revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY22 ...Less

At 09:45 am, shares of Biocon were trading 3.9 per cent higher at Rs 1,018.45. They hit a low of Rs 978 a ...More

At 09:45 am, shares of Biocon were trading 3.9 per cent higher at Rs 1,018.45. They hit a low of Rs 978 and a 52-week high of Rs 1,018.80 in the first 30 minutes of trade. ...Less

According to ET Now poll, the company is likely to report a net profit of Rs 95.8 crore, up 7 per cent, a ...More

According to ET Now poll, the company is likely to report a net profit of Rs 95.8 crore, up 7 per cent, as compared to a net profit of Rs 89.6 crore in the corresponding quarter last fiscal. ...Less

Consolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration. ...More

Consolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration. ...Less

Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and ...More

Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a strong product pipeline, including new offerings expected to drive growth. The company is also refinancing debt to lower costs and exploring fund-raising options through asset sales. Positive growth is anticipated in the biosimilars business starting in 2H FY25. ...Less

Biocon reported a strong turnaround in Q2FY26 with a net profit of Rs 84.5 crore against a loss of Rs 16 ...More

Biocon reported a strong turnaround in Q2FY26 with a net profit of Rs 84.5 crore against a loss of Rs 16 crore last year, driven by 21% YoY revenue growth to Rs 4,389 crore. Biosimilars led with 61% of revenue. The company also repaid key debts, aiming to boost margins and cut interest costs by FY27. ...Less

Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosi ...More

Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services businesses. ...Less

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 ...More

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and generics. Net profit surged 428% to Rs 85 crore, boosted by debt settlement and strategic partnerships for affordable insulin access in the US. The company also inaugurated its first US OSD manufacturing facility and commenced Semaglutide filings. ...Less

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 c ...More

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...Less